Dimebon shows positive data in Alzheimer’s study

A drug once approved as an antihistamine in Russia improved thinking processes and ability to function in patients with Alzheimer's disease in a study conducted there, said an expert at Baylor College of Medicine in Houston. The findings are published in the journal The Lancet.

"More research is needed, but we are encouraged by the effect the drug Dimebon had on Alzheimer's patients," said Dr. Rachelle Doody, professor of neurology at BCM and lead author of the study. In the study, the authors noted that Dimebon is the first drug for Alzheimer's disease that demonstrated continued improvement in patients over a 12 month period. Other approved drugs do not have this effect.

- read the release

Suggested Articles

MyoKardia wasn’t looking for a buyout when it started discussing potential partnerships with Bristol Myers Squibb last year.

The patient was hospitalized with febrile neutropenia in the weeks after receiving the drug and died 52 days post-treatment with the CAR-T therapy.

The trial has been paused since early September while FDA reviews the safety of the vaccine in light of a reported case of an inflammatory disorder.